Recombinant Nucleic Acids with Mitochondrial Targeting for LHON
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Leber's hereditary optic neuropathy (LHON) have limited transfection efficiency and efficacy, particularly due to the mitochondrial nature of the disease, which affects young adult males predominantly, with mutations in the ND4, ND1, and ND6 genes leading to significant vision loss.
Innovation Solution
Development of recombinant nucleic acids with mitochondrial targeting sequences and 3'UTR nucleic acid sequences, encoded to be at least 90-100% identical to specific sequences, for use in adeno-associated virus (AAV) vectors to deliver therapeutic genes to mitochondria, enhancing transfection efficiency and treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatment compositions are used for LHON, then the treatment can be administered, but the transfection efficiency and treatment efficacy are limited
Solution Approach 1:
The patent applies local quality by incorporating a mitochondrial targeting sequence (MTS) at the N-terminus of the ND1 protein coding sequence. This MTS directs the therapeutic protein specifically to mitochondria, concentrating the treatment effect at the disease site while leaving other cellular functions unchanged. This localized targeting resolves the contradiction by enhancing treatment efficacy through precise mitochondrial delivery without compromising overall transfection efficiency
Solution Approach 2:
The patent uses adeno-associated virus (AAV) vectors as intermediaries to deliver the recombinant nucleic acid encoding the ND1 protein with MTS to retinal ganglion cells. The AAV vector acts as a mediator that facilitates efficient transfection into mitochondrial targets, thereby improving both transfection efficiency and subsequent treatment efficacy for LHON
2Manufacturing precision
If mitochondrial targeting is implemented to improve treatment specificity, then treatment precision increases, but the complexity of the nucleic acid construct increases
Solution Approach 1:
The recombinant nucleic acid construct is segmented into distinct functional modules: a mitochondrial targeting sequence (MTS) segment, a coding sequence for NADH dehydrogenase subunit 1 (ND1) protein, and a 3' untranslated region (3'UTR). This segmentation allows each component to perform its specific function independently while simplifying the overall design and manufacturing process. The MTS segment directs mitochondrial localization, the coding segment produces the therapeutic protein, and the 3'UTR ensures proper expression regulation
Solution Approach 2:
The mitochondrial targeting sequence (MTS) serves multiple functions simultaneously: it directs the protein to mitochondria, facilitates proper protein folding, and enhances protein stability. This multi-functionality reduces the need for additional separate elements in the construct, thereby maintaining treatment precision while minimizing construct complexity
3Productivity
If viral vectors are used to enhance gene delivery, then transfection efficiency improves, but viral titer stability during storage and handling becomes challenging
Solution Approach 1:
The patent employs adeno-associated virus (AAV) vectors, which are known for their robust stability compared to other viral vectors. AAV particles are cushioned against environmental stresses through their protein capsid structure, which protects the genetic material during freeze/thaw cycles and storage. This beforehand cushioning allows the viral vector to maintain transfection efficiency while preserving viral titer stability during storage and handling
Data Source
AI summary
Disclosed herein is a recombinant nucleic acid, comprising: a mitochondrial targeting sequence; a mitochondrial protein coding sequence, wherein said mitochondrial protein coding sequence encodes a polypeptide comprising a mitochondrial protein; and a 3′UTR nucleic acid sequence. Also disclosed is a pharmaceutical composition comprising the recombinant nucleic acid and a method of treating Leber's hereditary optic neuropathy (LHON) using the pharmaceutical composition.